Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188)

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 5973-5982

  Davidson, Nancy E ^a   O'Neill, Anne M ^a   Vukov, Allen M ^a   Osborne, C Kent ^a   Martino, Silvana ^a   White, Douglas R ^a   Abeloff, Martin D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GOSERELIN; STEROID RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CAF PROTOCOL; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ALOPECIA; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FEMALE; FEVER; GRANULOCYTOPENIA; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; PATIENT COMPLIANCE; PNEUMONIA; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SEPSIS; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT GAIN; ADULT; AXILLA; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GOSERELIN; HUMANS; LYMPHATIC METASTASIS; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 24944509667     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.551     Document Type: Article

References (32)

1. Clarke MJ: Ovarian ablation in breast cancer, 1896-1998: Milestones along hierarchy of evidence from case report to Cochrane review. BMJ 317:1246-1248, 1998
2. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976
3. Fisher B, Carbone P, Economour SG, et al: L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 292:117-122, 1975
4. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 319: 1681-1692, 1988
5. Adjuvant chemotherapy for breast cancer. NIH Consensus Statement, September 9-11; 5:1-19, 1985
6. Taylor CW, Green S, Dalton WS, et al: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An Intergroup study. J Clin Oncol 16:1293-1298, 1993
7. Fetting JH, Gray R, Fairclough DL, et al: Sixteen-week multidrug regimen versus cyclophophamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: An Intergroup study. J Clin Oncol 16:2382-2391, 1998
8. Cox DR, Snell EJ: Analysis of Binary Data (ed 2). London, UK, Chapman and Hall, 1989
9. Mehta CR, Patel NR, Tsiatis AA: Exact significance testing for ordered categorical data. Biometrics 40:819-825, 1984
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
12. Cox DR: Regression models and life-tables (with discussion). J Royal Stat Soc B 34:181-220, 1972
13. Wald A: Tests of statistical hypotheses concerning several parameters when the number of parameters is large. Trans of Am Math Soc 54:426-482, 1943
14. Bonetti M, Gelber RD: A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19:2595-2609, 2000
15. Early Breast Cancer Trialists's Collaborative Group. Systematic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
16. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351: 1451-1467, 1998
17. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
18. Day R, Ganz P, Costantino JP, et al: Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Clin Oncol 17:2659-2669, 1999
19. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942, 1998
20. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomized trials. Lancet 348: 1189-1196, 1996
21. Scottish Cancer Trials Breast Group and ICRF, Breast Unit, Guy's Hospital, London: Adjuvant ovarian ablation versus CM chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish Trial. Lancet 341:1293-1298, 1993
22. Jonat W, Kaufmann M, Sauerbrei W, et al: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node positive breast cancer: The Zoladex Early Breast Cancer Res Association study. J Clin Oncol 24: 4628-4635, 2002
23. Ejlertsen B, Dombernowsky P, Mouridsen HT, et al: Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proc Am Soc Clin Oncol 18:66a, 1999 (abstr 248)
24. Castiglione-Gertsch M, O'Neill A, Price KN, et al: Adjuvant chemotherapy followed by goserelin, versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 95:1833-1846, 2003
25. Schmid P, Untch M, Wallwiener D, et al: Cyclophosphamide, methotrexate and flurouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node positive, premenopausla breast cancer patients: Preliminary results of the TABLE study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res 22:2325-2332, 2002
26. Boccardo F, Rubagotti A, Amoroso D, et al: Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjvuant Study Group 02 randomized trial. J Clin Oncol 18:2718-2727, 2000
27. Jakesz R, Hausmaninger H, Kubista E, et al: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 24: 4621-4627, 2002
28. Roche HH, Kerbrat P, Bonneterre J, et al: Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients (pts) with positive hormone-receptor (HR+) and 1-3 node-positive (N+) tumor: Results of the FASG 06 trial. Proc Amer Soc Clin Oncol 19:72a, 2000 (abstr 279)
29. Baum M: Adjuvant treatment of premenopausal breast cancer with Zoladex and tamoxifen. Breast Cancer Res Treat 57:30, 1999
30. Arriagada R, Le MG, Spielmann M, et al: Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 16:389-396, 2005
31. Tormey DC, Gray R, Abeloff MD, et al: Adjuvant therapy with a doxorubicin regimen and long-term tamoxiten in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. J Clin Oncol 10:1848-1856, 1992
32. Albain KS, Green SJ, Ravdin PM, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG 8814). Proc Am Soc Clin Oncol 21:37a, 2002 (abstr 143)